Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
OTC Markets
ETFs
Canadian ETFs
US ETFs
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Real Time & Level II Data
Showcase Companies
DealRoom
News Focus
Early opportunity to invest in a Nevada lithium project (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Jazz Pharmaceuticals plc
JAZZ
Healthcare
Biotechnology
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology...
. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:JAZZ)
New Post
View:
Posts & Comments
Threaded Posts
(11)
•••
Wrywisdom
X
Post by
Wrywisdom
on Jul 13, 2022 2:02pm
ENTG Extends Primary Credit Facility with BMO/Others 2+Years
For those not aware, Entourage has extended and improved it's primary credit facility with Bank of Montreal for two more years, furthering it's relationship with one of Canada's most
...more
(54)
•••
Bullknit101
X
Post by
Bullknit101
on Sep 30, 2021 8:17am
Cannabinoid Pharma
To my knowledge, InMed Pharma is the only company conducting clinical trials with rare cannabinoids which they can also manufacture. Epidiolex is CBD ia based. https://www.globenewswire.com/news
...more
(0)
•••
goregil
X
Post by
goregil
on Feb 14, 2019 1:18am
Next multibagger
https://stockhouse.com/news/press-releases/2019/01/31/patient-five-cancer-free-twelve-months-after-single-anti-cancer-treatment
Thank You
Your Report has been submitted.
Report Abusive Content
×
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}}
{{story.headline}}
< Previous bulletin
Next bulletin >
The Power Play by The Market Herald
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video
{{moreVideoText}}
Next Video >
Featured News Links
Canada Nickel Continues to Intersect High-grade, Near-surface Mineralization at Texmont Project
DehydraTECH Licensing Revenues increases 5x and Hits Another Quarterly Record with New Licensees
Exclusive Insights on the Precious Metals Industry and What to Expect in 2023 – Download free report